FDA Accepts Supplement for Lebrikizumab by Eli Lilly
The FDA has accepted the supplemental biologics application for Lebrikizumab (BLA761306) from Eli Lilly.
Therapeutic Area
Therapeutic area intelligence for IL-23 with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.